Clinical trials: Small Cell Carcinoma of Lung
EGFR Mutation Positive Non-small Cell Lung Cancer
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.
- Trial name
- NCT01776684
- Testing
- EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Carcinoma, Non-Small-Cell Lung
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant…
- Trial name
- Cybertaxcis II (NCT06627738)
- Testing
- Cyberknife irradiation
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Antoine Lacassagne
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
This study aims to evaluate the efficacy and safety of DS-1062a in participants with metastatic, unresectable NSCLC having progressed on one, but not more than three previous standard therapies.
- Conditions
- Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer
- Trial name
- ICARUS-LUNG01 (NCT04940325)
- Testing
- DS-1062a
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non-small Cell Lung Cancer
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery.
- Trial name
- INTerpath-014 (NCT07513376)
- Testing
- Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa
- Where
- 124 sites in United States, Australia and 18 more
- Volunteers
- 876 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Gold sodium thiomalate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of gold sodium thiomalate in…
- Trial name
- NCT00575393
- Testing
- gold sodium thiomalate, gene expression analysis, fluorine F 18 fluorothymidine
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Small Cell Lung Cancer
Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
The scope of the PICASSO project is to apply an innovative patient-based pan-omic approach to immune-assays, that will include multi-omics tumour characterization (genome, proteome, transcriptome), blood immune-cells and cytokine…
- Trial name
- PICASSO (NCT05797493)
- Testing
- Atezolizumab
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
SCLC
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
IBI110 is an investigational drug under evaluation for treatment of small cell lung cancer. The purpose of the study was to assess the Efficacy and Safety of IBI110 in combination with Sintilimab and chemotherapy with untreated…
- Trial name
- NCT05026593
- Testing
- Carboplatin, Cisplatin, Etoposide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small Cell Lung Cancer
A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy of anti-emetic drug Aprepitant upon the combination chemotherapy of nedaplatin and docetaxel for non-small cell lung cancer (NSCLC).
- Trial name
- NCT02364804
- Testing
- Aprepitant
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Shiga University
Non-small Cell Lung Cancer
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
To assess the efficacy and safety of SH-1028 tablets versus placebo in stage II-IIIB non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations, following complete tumor…
- Trial name
- NCT06080776
- Testing
- SH-1028 tablets
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis
Collection of ctDNA and TCR data to predict the efficacy and prognosis of brain radiotherapy in patients with brain metastases from non-small cell lung cancer (NSCLC) in a comprehensive manner
- Trial name
- NCT05737589
- Testing
- Whole-brain radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xiaorong Dong
Non Small Cell Lung Cancer
Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
The purpose of this study is to find out if giving reolysin in combination with docetaxel or pemetrexed can offer better results than standard therapy with docetaxel or pemetrexed alone.
- Trial name
- NCT01708993
- Testing
- Pemetrexed and Reolysin (and safety run-in), Pemetrexed, Docetaxel and Reolysin
- Where
- 12 sites in Canada
- Volunteers
- 166 people
- Sponsor
- Canadian Cancer Trials Group
SCLC, Extensive Stage
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
SCLC has a very high degree of malignancy, and 60% to 70% of patients are diagnosed as extensive stage. The median survival of patients with limited-stage disease is about 15-20 months, and the median OS of patients with…
- Trial name
- NCT05299255
- Testing
- Utidelone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell
Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
Nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer, especially for squamous cell cancer.
- Trial name
- NCT01494415
- Testing
- Paclitaxel for Injection（Albumin Bound）, carboplatin, thoracic radiation therapy
- Where
- 2 sites in China
- Volunteers
- 21 people
- Sponsor
- First People's Hospital of Hangzhou
Lung Cancer
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing.
- Trial name
- NCT00006049
- Testing
- carboplatin, gefitinib, paclitaxel
- Where
- United States
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by RECIST criteria in patients with advanced NSCLC Stage…
- Trial name
- NCT00525148
- Testing
- BIBW 2992
- Where
- 30 sites in United States, Taiwan
- Volunteers
- 129 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes
This is a retrospective, cross-sectional, non-interventional, multi-country survey-based chart audit study to evaluate real-world treatment patterns, patient clinical profiles, and clinical outcomes among a NSCLC patients…
- Trial name
- UNCOVER (NCT07215026)
- Where
- India
- Volunteers
- 833 people
- Sponsor
- AstraZeneca
Lung Cancer, Small-cell Lung Cancer
Study of Trilaciclib and Lurbinectidin
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer.
- Trial name
- NCT05578326
- Testing
- Trilaciclib, Lurbinectedin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung, Docetaxel
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
This study is a randomized, single-center, open-label, phase II clinical trial designed to evaluate non-small cell lung cancer that has failed to undergo excessive platinum-based chemotherapy and has not received excessive statin…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Docetaxel, Nivolumab
- Trial name
- NCT04023617
- Testing
- Nivolumab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
This is a blood collection study being conducted to better understand and describe the immunological blood profile changes in patients with advanced non small cell lung cancer undergoing treatment with checkpoint inhibitor…
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Healthy
- Trial name
- NCT04187768
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Indiana University
Non-small Cell Lung Cancer
Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
This is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung…
- Trial name
- NCT03924050
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.